Evidence map›Paper›PMID 38225952›Full record

ArticleThe World Allergy Organization journal2024

Clinical benefits with 300 IR HDM SLIT tablet in Europeans with house dust mite allergic rhinitis: Post hoc analysis of a large phase 3 trial.

Oliver Pfaar, Frédéric De Blay, Giorgio Walter Canonica, Thomas B Casale, Philippe Gevaert, Peter W Hellings, Krzysztof Kowal, Giovanni Passalacqua, Miguel Tortajada-Girbés, Carmen Vidal and 3 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The World Allergy Organization journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02443805 (A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02443805 phase3completednot on this map

A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis

TypeinterventionalSponsorStallergenes GreerRan2015 to 2018Enrolled1,607ConditionsRhinitis, Allergic, Perennial, House Dust Mite AllergyArms300 IR, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 12 institutions in 7 countries.

Oliver PfaarDepartment of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, D-35043 Marburg, Germany.
Frédéric De BlayChest Diseases Department, Federation of Translational Medicine EA 3072, Strasbourg University Hospital, 67000 Strasbourg, France.
Giorgio Walter CanonicaDepartment of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy.
Thomas B CasaleDivision of Allergy and Immunology, University of South Florida, Tampa, FL 33612, USA.
Philippe GevaertUpper Airway Research Laboratory (URL), Department of Otorhinolaryngology, Ghent University, 9000 Ghent, Belgium.
Peter W HellingsUpper Airway Research Laboratory (URL), Department of Otorhinolaryngology, Ghent University, 9000 Ghent, Belgium.
Krzysztof KowalDepartment of Experimental Allergology and Immunology, Medical University of Bialystok, Sklodowskiej-Curie 24, 15-369 Bialystok, Poland.
Giovanni PassalacquaAllergy and Respiratory Diseases, IRCCS Policlinico San Martino, University of Genoa, Genoa, Italy.
Miguel Tortajada-GirbésDepartment of Pediatrics, Dr. Peset University Hospital, 46017 Valencia, Spain.
Carmen VidalAllergy Department and Faculty of Medicine, Complejo Hospitalario Universitario de Santiago, Instituto de Investigación de Santiago (IDIS) and University of Santiago, 15706 Santiago de Compostela, Spain.
Margitta WormDivision of Allergy and Immunology, Department of Dermatology and Allergology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.
Farah BahbahIndependent Researcher, Paris, France.
Pascal DemolyUniversity Hospital of Montpellier and IDESP, UMR UA11, University of Montpellier - INSERM, Montpellier, France.
Charité - Universitätsmedizin Berlin · DEGhent University · BEHumanitas University · ITInserm · FRMedical University of Białystok · PLOspedale Policlinico San Martino · ITPhilipps University of Marburg · DEUniversidade de Santiago de Compostela · ESUniversitair Ziekenhuis Leuven · BEUniversitat de València · ESUniversité de Strasbourg · FRUniversity of South Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: House dust mite (HDM)-induced allergic rhinitis (AR) is a major cause of allergic respiratory disease. The efficacy and safety of the 300 IR HDM sublingual immunotherapy (SLIT) tablet in patients with moderate-to-severe HDM-AR was confirmed in a large, international, phase 3 randomized controlled trials (RCTs). Here, we analyzed the results in the European population. Methods: Data from 91 European centers that participated in the international, double-blind, RCT (EudraCT 2014-004223-46, NCT02443805) with the 300 IR HDM SLIT tablet versus placebo over 12 months were analyzed post hoc. The treatment effect in European adults and adolescents was notably assessed through the European Academy of Allergy and Clinical Immunology (EAACI)-recommended combined symptom and medication score (CSMS Results: There were 818 patients who comprised the modified full analysis set in Europe. Over the primary period, the differences in CSMS Conclusion: This RCT sub-analysis confirmed the 300 IR HDM SLIT tablet is an effective and safe treatment for European adults and adolescents with HDM-AR with clinically meaningful benefits from the patients' perspective. Trial registration: NCT02443805. Registered on April 29, 2015./EudraCT 2014-004223-46. Registered on September 16, 2015.

Indexed as

Allergic rhinitisCombined scoreHouse dust miteQuality of lifeSublingual immunotherapy tablet

Identifiers

PMID38225952
PMCPMC10788274
OpenAlexW4390122250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.